Illustrative image – not actual.Bangalore-based company, Biocon India and Hyderabad-based
company, Shantha Biotechnics, announced a 50:50 joint venture (JV), on 10 April
2002 to manufacture human insulin in India. The JV company will be called
Biocon-Shantha Biotech Ltd.
The joint venture will also leverage the
existing capabilities of both companies and an additional investment of Rs.20
crore would also be made, according to Mr Varaprasad Reddy, Managing Director,
Shantha Biotech.
Shantha has been working on human insulin for
the last three years and has developed a lab scale product. However, the company
does not have the capacity to produce it on a larger scale. This is where
Biocon will play a major role. Commercial production is expected to commence by
December 2002. The bulk insulin will be sent back to Shantha for quality
testing, vialling and labelling, after which, it will be marketed by both companies
in India.
Currently, the only human insulin that is available in the country is imported and is an expensive one. The other less expensive variety is the one derived from cows and pigs.
